{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T07:35:50Z","timestamp":1793172950747,"version":"4.5.0"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To examine the prevalence of hydroxychloroquine (HCQ) retinopathy due to its chronic use in various inflammatory conditions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>It was a cross-sectional, observational study evaluating 80 patients for retinopathy using optical coherence tomography, fundus autofluorescence, and visual field analysis tests.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The Chi-squared test was employed, and a\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      value of &lt;0.05 was considered significant. In our study, a total of 7 patients (8.75%) had definite retinopathy, while eight patients (10%) had possible retinopathy. All seven patients with definite retinopathy and seven out of eight patients with possible retinopathy were female. Most subjects with definite retinopathy were in the 51\u201360-year age group (57%), and the majority resided in rural areas. The majority of patients with retinopathy had rheumatoid arthritis. Retinopathy was found to be associated with the mean daily dose of HCQ (based on actual body weight) and the duration of HCQ use. All patients with definite retinopathy, as well as seven out of eight patients with possible retinopathy, were using more than 6 mg\/kg\/day, which exceeds the recommended daily dose of greater than 5 mg\/kg. Most of our patients (6 out of 7, or 85.7%) with definite retinopathy had been on HCQ for more than 10 years. Among the subjects with definite retinopathy, 71.4% had a pericentral pattern, 28.5% had a parafoveal pattern, and none had a mixed pattern.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>HCQ retinopathy is more prevalent at a mean daily dose of &gt;5 mg\/kg and with prolonged use of &gt;5 years. Thus, timely screening of patients for retinopathy will help in modifying the dosage or in drug cessation, thus preventing its progression.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijo.ijo_1355_25","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T12:00:42Z","timestamp":1784894442000},"page":"1621-1626","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Toxic retinopathy associated with long-term hydroxychloroquine therapy"],"prefix":"10.4103","volume":"74","author":[{"given":"Sidra J","family":"Thakur","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, SKIMS Medical College and Hospital, Srinagar, Jammu and Kashmir, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imtiyaz Ahmad","family":"Lone","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, SKIMS Medical College and Hospital, Srinagar, Jammu and Kashmir, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"key":"R1-20261028","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1177\/0961203312437270","article-title":"Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: Data from LUMINA (LXXV), a multiethnic US cohort","volume":"21","author":"Willis","year":"2012","journal-title":"Lupus"},{"key":"R2-20261028","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.ophtha.2016.01.058","article-title":"Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 Revision)","volume":"123","author":"Marmor","year":"2016","journal-title":"Ophthalmology"},{"key":"R3-20261028","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1136\/ard.2006.068676","article-title":"Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: Data from LUMINA, a multiethnic US cohort (LUMINA L)","volume":"66","author":"Alarc\u00f3n","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"R4-20261028","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1136\/bjophthalmol-2013-303897","article-title":"Cystoid macular oedema and epiretinal membrane formation during progression of chloroquine retinopathy after drug cessation","volume":"98","author":"Kellner","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"R5-20261028","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/0002-9343(83)91267-6","article-title":"Ophthalmologic considerations and testing in patients receiving long-term antimalarial therapy","volume":"75","author":"Bernstein","year":"1983","journal-title":"Am J Med"},{"key":"R6-20261028","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1001\/archophthalmol.2011.371","article-title":"Comparison of screening procedures in hydroxychloroquine toxicity","volume":"130","author":"Marmor","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"R7-20261028","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/art.39402","article-title":"Association of polymorphisms of cytochrome P450 2D6 with blood hydroxychloroquine levels in patients with systemic lupus erythematosus","volume":"68","author":"Lee","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"R8-20261028","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1001\/jamaophthalmol.2014.1099","article-title":"Effect of disease stage on progression of hydroxychloroquine retinopathy","volume":"132","author":"Marmor","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"R9-20261028","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.ophtha.2020.10.029","article-title":"Long-term progression of pericentral hydroxychloroquine retinopathy","volume":"128","author":"Ahn","year":"2021","journal-title":"Ophthalmology"},{"key":"R10-20261028","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1038\/s41433-020-01380-2","article-title":"The Royal College of Ophthalmologists recommendations on monitoring for hydroxychloroquine and chloroquine users in the United Kingdom (2020 revision): Executive summary","volume":"35","author":"Yusuf","year":"2021","journal-title":"Eye"},{"key":"R11-20261028","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/s41433-020-1038-2","article-title":"Prevalence of hydroxychloroquine retinopathy using 2018 Royal College of Ophthalmologists diagnostic criteria","volume":"35","author":"Marshall","year":"2021","journal-title":"Eye"},{"key":"R12-20261028","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/IAE.0000000000002408","article-title":"Sequential changes in hydroxychloroquine retinopathy up to 20 years after stopping the drug: Implications for mild versus severe toxicity","volume":"39","author":"Pham","year":"2019","journal-title":"Retina"},{"key":"R13-20261028","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1001\/archopht.125.6.775","article-title":"High-speed ultra-high-resolution optical coherence tomography findings in hydroxychloroquine retinopathy","volume":"125","author":"Rodriguez-Padilla","year":"2007","journal-title":"Arch Ophthalmol"},{"key":"R14-20261028","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.2147\/OPTH.S14257","article-title":"Spectral domain optical coherence tomography as an effective screening test for hydroxychloroquine retinopathy (the \u201cflying saucer\u201d sign)","volume":"4","author":"Chen","year":"2010","journal-title":"Clin Ophthalmol"},{"key":"R15-20261028","doi-asserted-by":"crossref","first-page":"100907","DOI":"10.1016\/j.preteyeres.2020.100907","article-title":"Fundus-controlled perimetry (microperimetry): Application as outcome measure in clinical trials","volume":"82","author":"Pfau","year":"2021","journal-title":"Prog Retin Eye Res"},{"key":"R16-20261028","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.ophtha.2013.12.002","article-title":"Disparity between visual fields and optical coherence tomography in hydroxychloroquine retinopathy","volume":"121","author":"Marmor","year":"2014","journal-title":"Ophthalmology"},{"key":"R17-20261028","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jfo.2015.01.005","article-title":"Clinical evaluation of the new screening procedures for hydroxychloroquine retinopathy, according to the American Academy of Ophthalmology guidelines. Prospective study of 184 patients","volume":"38","author":"Jaumouill\u00e9","year":"2015","journal-title":"J Fr Ophtalmol"},{"key":"R18-20261028","doi-asserted-by":"crossref","first-page":"e395","DOI":"10.1097\/RHU.0000000000001479","article-title":"Screening for hydroxychloroquine retinal toxicity in Indian patients","volume":"27","author":"Dadhaniya","year":"2021","journal-title":"J Clin Rheumatol"},{"key":"R19-20261028","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ophtha.2014.07.018","article-title":"Pericentral retinopathy and racial differences in hydroxychloroquine toxicity","volume":"122","author":"Melles","year":"2015","journal-title":"Ophthalmology"},{"key":"R20-20261028","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.ophtha.2015.01.014","article-title":"Pericentral hydroxychloroquine retinopathy in Korean patients","volume":"122","author":"Lee","year":"2015","journal-title":"Ophthalmology"},{"key":"R21-20261028","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/acr.20133","article-title":"Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus","volume":"62","author":"Wolfe","year":"2010","journal-title":"Arthritis Care Res"},{"key":"R22-20261028","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/eye.2016.298","article-title":"Hydroxychloroquine retinopathy","volume":"31","author":"Yusuf","year":"2017","journal-title":"Eye"},{"key":"R23-20261028","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.ajo.2015.07.012","article-title":"Rapid onset of retinal toxicity from high-dose hydroxychloroquine given for cancer therapy","volume":"160","author":"Leung","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"R24-20261028","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1001\/jamaophthalmol.2014.3459","article-title":"The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy","volume":"132","author":"Melles","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"R25-20261028","first-page":"41","article-title":"Retinal toxicity in patients treated with hydroxychloroquine: A cross-sectional study","volume":"5","author":"Espandar","year":"2016","journal-title":"Med Hypothesis Discov Innov Ophthalmol"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_1355_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T07:00:13Z","timestamp":1793170813000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_1355_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_1355_25","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]},"assertion":[{"value":"2025-05-30","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-11","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}